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OBJECTIVE — To assess the additional effect of sudden visceral fat reduction by omentec-
tomy on metabolic syndrome, acute-phase reactants, and inﬂammatory mediators in patients
with grade III obesity (G-III O) undergoing laparoscopic Roux-en-Y gastric bypass (LRYGB).
RESEARCH DESIGN AND METHODS — Twenty-two patients were randomized
into two groups, LRYGB alone or with omentectomy. Levels of interleukin-6, C-reactive
protein, tumor necrosis factor-, leptin, adiponectin, glucose, total cholesterol, HDL cho-
lesterol, LDL cholesterol, and triglycerides, as well as clinical characteristics, were evaluated
before surgery and at 1, 3, 6, and 12 months after surgery. Results were compared between
groups.
RESULTS — Baseline characteristics were comparable in both groups. Mean operative time
was signiﬁcantly higher in the group of patients who underwent omentectomy (P  0.001).
Median weight of the omentum was 795  341 g. In one patient, a duodenal perforation
occurred at the time of omentectomy. BMI, blood pressure, glucose, total cholesterol, LDL, and
triglycerides signiﬁcantly improved in both groups at 1, 3, 6, and 12 months of follow-up when
compared with basal values. However, there were no consistent statistically signiﬁcant differ-
ences among the groups in terms of metabolic syndrome components, acute-phase reactants,
and inﬂammatory mediators.
CONCLUSIONS — Omentectomy does not have an ancillary short-term signiﬁcant impact
on the components of metabolic syndrome and does not induce important changes in the
inﬂammatory mediators in patients undergo-
ing LRYGB. Operative time is more prolonged
when omentectomy is performed.
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M
etabolicsyndromeisanimportant
comorbid condition of grade III
obesity (G-III O). There are sev-
eral deﬁnitions for metabolic syndrome,
which include a constellation of meta-
bolic abnormalities such as glucose intol-
erance (type 2 diabetes, impaired glucose
tolerance, or impaired fasting glycae-
mia), insulin resistance, central obesity,
dyslipidemia, and hypertension, all
well-documented risk factors for car-
diovascular disease (1–3).
Surgical weight reduction improves
metabolicsyndromeinpatientswithG-III
O.Inparticular,theRoux-en-Ygastricby-
pass has shown in addition to endurable
weight reduction (4) a signiﬁcant positive
impact on the components of the syn-
drome (5). The beneﬁt from weight re-
duction in this group of patients has been
related to changes in the plasmatic levels
of adipocytokines (i.e., tumor necrosis
factor[TNF]-,interleukin[IL]-6,retinol
binding protein-4, among others). These
are produced in both visceral and subcu-
taneous fat, which are believed to partic-




with insulin resistance, glucose intoler-
ance, dyslipidemia, and cardiovascular
disease. The mechanism by which in-
creased central adiposity causes hepatic
insulin resistance is unclear, but there are
at least two major hypotheses to explain
it. The “portal hypothesis” suggests that
an increased delivery of free fatty acids by
visceral adipose tissue to the portal vein
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hypothesis implies that secretion of adi-
pokines may induce hepatic insulin resis-
tance (9). Removal of subcutaneous fat
has failed to improve metabolic syn-
drome. This was proved by Klein et al.
(10) who performed massive liposuction
to a group of patients with metabolic syn-
drome,withverylittleornoimpactonthe
components of the syndrome. Tho ¨rne et
al. (11), on the other hand, in a random-
ized controlled trial, performed omentec-
tomy to a group of patients who
underwent adjustable gastric banding.
The authors found a positive impact of
omentectomy on metabolic syndrome in
the long term (11).
RESEARCH DESIGN AND
METHODS— We conducted a pro-
spective, controlled, randomized pilot
trial to evaluate the additional effect of
suddenvisceralfatreductionbyomentec-
tomy on metabolic syndrome in patients
with G-III O undergoing laparoscopic
Roux-en-Y gastric bypass (LRYGB). A to-
tal of 24 patients, with BMI 40 kg/m
2
and metabolic syndrome according to the
Adult Treatment Panel III classiﬁcation
were invited to participate in the study
(see online appendix at http://care.
diabetesjournals.org/cgi/content/full/
dc09-1833/DC1). They were patients
whowerescheduledtoLRYGBperformed
by two of the authors (M.F.H. and J.P.P.)
and were enrolled between December
2005 and October 2006. Patients were
randomized at their arrival to the operat-
ing room by the surgeon using sequen-
tiallynumberedsealedenvelopesintotwo
groups, LRYGB alone or LRYGB with
omentectomy. The randomization se-
quence was computer generated and
blocked in groups of eight. All patients
signed an informed consent and the pro-
tocolwasapprovedbyourinstitutionsre-
view board.
Body weight and height were mea-
sured using a daily calibrated balance
(Tanita TBF310) and BMI was estimated.
Blood pressure was measured in a sitting
position using a sphygmomanometer and
a stethoscope after a 10-min rest period.
LRYGB was performed according to the
following standards: gastric pouch was
constructed using the lesser curvature of
the stomach. A 45-mm stapler was ini-
tially ﬁred horizontally 2–3 cm below the
gastroesophageal junction, and then two
to three additional ﬁres toward the angle
ofHisandagainsta32Frenchintragastric
tube completed the vertical transection.
Lengths of the biliopancreatic and ali-
mentary limbs were 50 and 150 cm, re-
spectively. An antecolic and antegastric
gastrojejunostomy, 1.0–1.5 cm in size,
was hand sewn, and the jejuno-
jejunostomy was completed in a latero-
lateral fashion using one ﬁre of a 45-mm
lineal stapler with hand-sewn closure of
thecommonenterotomy.Alldefectswere
closed using nonabsorbable sutures. For
the omentectomy, the greater omentum
was divided in the middle from the free
edge to the colonic margin using ultra-
sonic energy. Attachments between the
omentum and the transverse colon were
dissected. The omentum was detached
from the stomach, transecting the vessels
between the right gastroepiploic vessels
and the greater curvature of the stomach.
Once the omentum was freed from the
stomach, the duodenum, and the lower
pole of the spleen, it was extracted from
the abdominal cavity in a sterile plastic
bag.
An oral glucose tolerance test using a
dose of 75 g of glucose after an overnight
fasting (12 h) period was performed in all
patients. Glucose and serum insulin con-
centrations were measured in blood sam-
ples obtained 10 min before and 0, 60,
and 120 min after the glucose intake. Di-
abetes was diagnosed when glucose was
200 mg/dl 2 h postload. Impaired fast-
ing glycemia was considered when the
basal glucose level was 100–125 mg/dl,
and impaired glucose tolerance was diag-
nosed when the 2-h postload glucose was
between 140 and 199 mg/dl.
Bloodsamplesforplasmaglucose,in-
sulin, lipid proﬁle (total cholesterol, HDL
cholesterol, LDL cholesterol, and triglyc-
erides), blood urea nitrogen, creatinine,
and liver function tests (total bilirubin,
transaminases, and albumin) were taken
after a 12-h fasting period before surgery
and at 1, 3, 6, and 12 months after sur-
gery.Thehomestasismodelassessmentof
Table 1—General characteristics of the studied groups
Omentectomy 
LRYGB LRYGB P
Age (years) 36.8  12.9 39.8  11.1 0.56
Sex (male/female) 3/8 1/10 0.58
BMI (kg/m
2) 44.9  3.1 44.5  4.3 0.79
Systolic blood pressure (mmHg) 131.8  9.8 134.6  6.9 0.46
Diastolic blood pressure (mmHg) 85.5  7.9 89  3.9 0.20
Glucose (mg/dl) 99.8  8.6 104.9  35.6 0.65
2-h glucose oral glucose tolerance test
(mg/dl) 172.6  53.9 170  39.8 0.92
Insulin (U/l) 21.64  9.8 22.0  12.4 0.94
Cholesterol (mg/dl) 182.8  36.6 192.3  55.4 0.64
Triglycerides (mg/dl) 180.4  83.8 292  248.3 0.18
HDL (mg/dl) 38.6  9.1 35.5  10.1 0.44
LDL (mg/dl) 106.8  32.3 126.6  49.9 0.30
Data are means  SD.
Table 2—Changes in comorbidities between groups at the end of the study period
Comorbidities
Before surgery 12 months after surgery
Total LRYGB
Omentectomy




tolerance 11/22 (50)* 7 4 1 (4.5) 0 0
Diabetes 10/22 (45.5)* 4 6 1 (4.5) 0 1
Hypertension 16/22 (72.7)* 8 8 3 (13.6) 2 1
Dyslipidemia 16/22 (72.7)* 6 10 2 (9.1) 1 1
Dataaren(%),unlessotherwiseindicated.*P0.001whencomparedwith12monthsaftersurgery(Fisher
exact test). Comparative analysis of LRYGB and Omentectomy  LRYGB before and after surgery  NS
(Fisherexacttest).Dyslipidemiawasconsideredwhenmeasurementsoftriglyceridesand/orcholesterolwere
above the upper normal limit values or when patients were under medical treatment with hypolipemiant
drugs.
Omentectomy and Roux-en-Y gastric bypass
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as a measure of insulin resistance.
Adiponectin, TNF-, leptin, C-reac-
tive protein (CRP), and IL-6 were mea-
sured at baseline and at 3, 6, and 12
months after LRYGB. Samples were col-
lected using standardized phlebotomy
procedures. Standard handling and pro-
cessingwasused.Serumandplasmawere
separatedbysamplespinning.Specimens
were immediately aliquoted, frozen, and
stored at 	80°C. For the multiplex anal-
ysis, we used the xMAP technology (Lu-
minex), which combines the principle of
a sandwich immunoassay with ﬂuores-
cent bead–based technology (12). The
xMAP serum assay for CRP, adiponectin,
leptin, IL-6, and TNF- was done in 96-
well microplate format according to the
protocol of LINCOplex kits (Linco, Milli-
pore,Billerica,MA).Theanalysiswasper-
formed using ﬁve-parametric-curve
ﬁtting. Interassay variabilities for individ-
ual cytokines were in the range of 7.0–
11.0% and intra-assay variabilities were
in the range of 8.2–14.6%. The limit of
detectionforPCR,TNF-,andIL-6was1
pg, for adiponectin 3.2 pg, and for leptin
16 pg.
Statistical analyses were conducted
using the Statistical Package for the Social
Sciences software (SPSS 16.0). Clinical
characteristics were compared among pa-
tients with and without omentectomy us-
ing Student t test. Changes in body
composition, metabolic syndrome mark-
ers, and adipocytokines were assessed by
Mann-Whitney U test. Correlations be-
tween changes in BMI and adipocyto-
kines were determinate by the Spearman
coefﬁcient. All reported P values are two
sided, and P  0.05 was considered sta-
tistically signiﬁcant.
RESULTS— Of 24 patients, 1 patient
of each group was lost for follow-up
(drop-out) after surgery. There were no
signiﬁcant differences between groups in
terms of age, sex, BMI, and laboratory
tests (Table 1).
Mean operative time was4h3 1m i n
a n d3h6min, respectively, in the group
of patients who underwent and did not
undergo omentectomy (P  0.001).
Mean weight of the resected omentum
was 795  341 g. There was one compli-
cation related to the omentectomy, a
duodenal perforation that required lapa-
roscopic revision for suturing.
As shown in Table 2, there was a sig-
niﬁcant impact of bariatric surgery on the
components of metabolic syndrome at
1-yearfollow-up.However,therewereno
differences between groups. BMI, systolic
blood pressure, diastolic blood pressure,
glucose, insulin, total cholesterol, LDL,
and triglycerides also had a signiﬁcant
changefrombasalvaluesat1,3,6,and12
months follow-up. However, there were
no statistical differences among the
groups in the majority of the analyzed
variables (Table 3). Isolated differences at
somepointsofthestudywerefound.LDL
values were signiﬁcantly lower 1 month
aftersurgeryinthegroupwhounderwent
omentectomy, which may be related to
thefactthatpreoperativevaluesofLDLin
thisgroupwerealsolower.Ascanbeseen
in Table 4, behavior of adipocytokines
throughout the studied period was also
very similar in both groups.
The relationship between weight loss
and changes in the studied variables was
assessed in the whole group, and a nega-
tive correlation was seen between BMI
and IL-6 at 3 months (P  0.013) and
BMI and TNF- at 12 months (P 
0.017). When we analyzed the data by
group, there was no correlation between
the behavior of the BMI and the analyzed
variables, except for IL-6 and BMI at 3
months (P  0.027) (RYGBP  omentec-
tomy),TNF-andBMIat12months(P
Table 3—Comparative analysis of metabolic variables between groups
Variables
Before surgery 1 month
Omentectomy  LRYGB LRYGB Omentectomy  LRYGB LRYGB
BMI (kg/m
2) 45.0  3.1 44.5  4.3 	10.9 (	14.7 to 	7.1) 	10.1 (	13.5 to 	6.7)
SBP (mmHg) 131.8  9.8 134.6  6.9 	7.6 (	40.2 to 25.0) 	14.9 (	33.3 to 3.6)
Glucose (mg/dl) 99.8  8.6 104.9  35.6 	3.2 (	18.6 to 12.3) 	15.8 (	40.9 to 9.2)
Insulin (U/l) 21.6  9.8 22.0  12.4 NA NA
Homeostasis model assessment of
insulin resistance 5.2  2.5 6.6  5.0 NA NA
Cholesterol (mg/dl) 182.8  36.6 192.3  55.4 	28.4 (	37.5 to 	19.3) 	16.9 (	24.4 to 	9.5)*
Triglyceride (mg/dl) 180.9  83.8 292  248.3 	33.9 (	56.8 to 	11.1) 	48.7 (	105.8 to 8.4)
HDL (mg/dl) 38.6  9.1 35.5  10.1 	19.7 (	31.9 to 	7.3) 	11.5 (	25.9 to 2.8)
LDL (mg/dl) 106.8  32.3 126.6  49.9 	29.3 (	43.8 to 	14.8) 	19.7 (	33.9 to 	33.9)*
Data after surgery are means  SD or percent of change from basal (95% CI). Minus signs denote decreases and plus signs increases. *P  0.05.
Table 4—Comparative analysis of adipocytokines between groups
Before surgery 3 months
Omentectomy  LRYGB LRYGB Omentectomy  LRYGB LRYGB
CRP (g/ml) 64.5  75.4 69.2  57.2 	62.2 (	118.2 to 	5.6) 	76.2 (	124.9 to 	27.5)
TNF- (pg/ml) 5.2  3.3 5.7  2.7 	1.9 (	40.4 to 36.5) 	12.3 (	36.8 to 10.5)
IL-6 (pg/ml) 4.8  9.5 8.9  16.9 247.9 (	264.6 to 762.5) 24.7 (	20.2 to 70.8)
Leptin (ng/ml) 55.4  30 103.6  153.1 	18.2 (	57 to 20.6) 	56.9 (	129.8 to 36.1)
Adiponectin (ng/ml) 10.7  5.1 9.5  4.8 42.1 (8.4–76.6) 66.3 (32.6–101.1)
Data after surgery are means  SD or percent of change from basal (95% CI). Minus signs denote decreases and plus signs increases. All comparisons P  NS.
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BMI at 1 month (P  0.033) (RYGBP 
omentectomy),andtriglyceridesandBMI
at 3 months (P  0.039) (RYGBP 
omentectomy).
CONCLUSIONS — Abdominal obe-
sity has been closely associated to meta-
bolic syndrome (1,3). Several studies
have demonstrated that surgically in-
duced weight reduction improves risk
factors from metabolic syndrome in mor-
bidly obese patients and that metabolic
syndrome can be controlled by bariatric
surgery in up to 95% of patients within
the ﬁrst year (13).
As it could be expected, when we an-
alyzed all patients together, there was a
signiﬁcant change in most components of
metabolic syndrome after surgery. A
meta-analysis published by Buchwald et
al. (4), as well as other clinical studies
(14), had already shown the positive ben-
eﬁt of bariatric surgery not only in terms
of weight loss but also for control of co-
morbid conditions.
Both subcutaneous and visceral fat
are responsible for the production of adi-
pocytokines, such as TNF-, IL-6, and
adiponectin (15,16). It has been shown
that they are markers of the inﬂammatory
stateinmetabolicsyndrome(17).Thereis
also evidence that surgically induced
weightlosshasanimportanteffectonadi-
pocytokines, reducing proinﬂammatory
CRP, TNF-, and IL-6 and increasing
anti-inﬂammatory adiponectin (18).
In terms of the effect of parietal fat
reduction on the components of meta-
bolic syndrome, Klein et al. (9) studied
the effect of massive liposuction on met-
abolic syndrome at 10–12 weeks on 15
obese women, 8 with normal glucose tol-
erance and 7 with diabetes. The amount
of fat removed was 9.1  3.7 kg and
10.5  3.3 kg in the nondiabetic and di-
abetic groups, respectively. Despite a sta-
tistically signiﬁcant reduction in BMI in
both groups, there were no signiﬁcant
changes in fasting glucose, total choles-
terol, HDL, LDL, and triglycerides 10–12
weeks after liposuction. In a similar way,
there were no signiﬁcant changes in adi-
pocytokines 10–12 weeks after the
procedure.
If the sudden reduction of parietal fat
doesnothaveaprevalentroleinthecom-
ponents of metabolic syndrome, sudden
reduction of visceral fat may be the evi-
dent target. Experimental studies in ani-
mals have demonstrated an impact of
removal the visceral fat on insulin resis-
tance. Barzilail et al. (19) found that sur-
gicalremovalofselectiveintra-abdominal
fat depots (perinephric and epididymal)
leads to a marked increase in the hepatic
effect of insulin and suggested that it
could regulate gene expression in subcu-
taneous adipose tissue in elderly obese
rats. Pitombo et al. (20) found the same
effect in rats with diet-induced diabetes
and their study also suggested favorable
modulation of adipokines. Kim et al. (21)
evaluated the role of visceral and subcu-
taneousfattissueonbothinsulinsensitiv-
ity and lipid metabolism. These authors
proved that visceral fat has a stronger ef-
fect on insulin sensitivity and concentra-
tion of free fatty acids in the liver than
subcutaneous fat in rats. Lottati et al. (22)
studied the metabolic impact of omentec-
tomy in nonobese dogs and found that
resection of visceral fat had a positive ef-
fect on insulin sensitivity.
In this study, we assessed if an addi-
tional effect could be obtained from
sudden visceral fat reduction (by omen-
tectomy) on the severity of the metabolic
syndromecomponents,acute-phasereac-
tants, and inﬂammatory mediators con-
centrations in patients with G-III O
undergoing LRYGB. Omentectomy does
not seem to have an ancillary short-term
signiﬁcant impact on the components of
metabolic syndrome and does not induce
Table 3—Continued
3 months 6 months
Omentectomy  LRYGB LRYGB Omentectomy  LRYGB LRYGB
	18.9 (	22.4 to 	14.9) 	18.7 (	23.1 to 	14.4) 	26.7 (	32.7 to 	23.2) 	25.6 (	29.7 to 	21.3)
	10.9 (	19.8 to 	2.0) 	14.9 (	109.2 to 79.6) 	17.7 (	21.2 to 	13.6) 	8.4 (	17.4 to 0.7)*
	12.3 (	19.3 to 	5.3) 	13.8 (	37.7 to 10.1) 	12.1 (	20.5 to 	3.7) 	18.5 (	38.6 to 1.7)
	64.8 (	111.6 to 	18.5) 	51.8 (	96.8 to 	6.8) 	57.4 (	88.0 to 	26.9) 	14.5 (	115.0 to 125.9)
	69.2 (	121.2 to 	19.2) 	54.5 (	106.1 to 1.5) 	59.6 (	155.8 to 	23.1) 	36.4 (	157.6 to 83.3)
	21.6 (	26.4 to 	16.8) 	12.7 (	21.7 to 	3.8) 	18.0 (	26.5 to 	16.8) 	10.6 (	21.6 to 0.5)
	39.4 (	61.1 to 	18.2) 	52.0 (	109.0 to 5.0) 	38.7 (	68.3 to 	9.0) 	45.6 (	109.9 to 19.0)
	9.8 (	24.1 to 4.1) 0.3 (	8.2 to 8.7) 	2.3 (	18.4 to 13.7) 15.5 (5.6–25.1)
	28.8 (	50.3 to 	7.3) 	14.2 (	22.4 to 	6.0) 	17.2 (	35.5 to 1.1) 	33.8 (	65 to 	2.6)
Table 4—Continued
6 months 12 months
Omentectomy  LRYGB LRYGB Omentectomy  LRYGB LRYGB
	65.6 (	152.1 to 	20.8) 	75.9 (	127.7 to 	23.8) 	80.0 (	196.7 to 36.7) 	86.27 (	143.4 to 	23.8)
	51.9 (	98.1 to 	5.8) 	17.5 (	40.4 to 3.5) 11.05 (	80.8 to 107.7) 	14.0 (	75.4 to 43.9)
104.2 (	285.4 to 493.8) 	23.6 (	93.3 to 46.1) 35.4 (	43.8 to 116.7) 	34.8 (	132.6 to 62.9)
	9.7 (	40.1 to 20.6) 	36.5 (	137.0 to 64.0) 16.8 (	30.9 to 64.4) 	21.8 (	145.8 to 102.0)
74.8 (40.2–109.3) 87.4 (46.3–127.4) 80.4 (30.8–129.0) 69.5 (	3.2 to 144.2)
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mediatorsinpatientsundergoingLRYGB.
In our study, values of LDL 3 and 6
months after surgery were signiﬁcantly
lowerinthegroupofpatientswhounder-
went omentectomy in addition to the
LRYGB, and there was also a tendency to-
ward a higher reduction of cholesterol
values in the same group of patients. On
the other hand, there were no signiﬁcant
differences on adipocytokine levels
throughout the studied period. Observed
differences in the behavior of LDL and
totalcholesterolmaynotbeofclinicalrel-
evance, since values were within the nor-
mal ranges in both groups from the ﬁrst
postoperative month.
What are the potential causes of the
lack of signiﬁcant differences on the post-
operative behavior of metabolic syn-
drome components between the studied
groups? An important limitation of our
study is the small number of studied pa-
tients. For example, homeostasis model
assessment of insulin resistance and insu-
linlevelsshowedatrendtowardmoreim-
provementinpatientsundergoingLRYGB
and omentectomy. An overt difference
may have been obscured by the small
number of patients (type II error). How-
ever, if the differences are so small that a
very large number of patients would be
required to make them evident, they may
not be sufﬁcient to justify the use of
omentectomy. This is particularly true if
weconsiderthatthereisanimportantim-
pact of weight reduction alone on meta-
bolic syndrome from the ﬁrst month after
LRYGB and that omentectomy is a time-
consuming procedure that may lead to
potentially lethal complications. An addi-
tional cause could be that in all experi-
mental studies omentectomy was
compared against a sham operation,
whereas in human studies it has been
compared with patients undergoing a
bariatric operation.
In terms of the impact of omentec-
tomy on adipocytokines, another aspect
that needs to be considered is that any
surgical procedure involves an inﬂamma-
tory reaction that may last for few weeks.
Iftheexpectedimpactofomentectomyon
inﬂammatory markers was more likely to
occur soon after surgery, surgical stress
may mask the real effect. As an additional
aspect related to the minimum or lack of
impact of omentectomy on adipocyto-
kines, it is worth mentioning that the
omentum accounts for a large proportion
of the intraabdominal visceral fat. How-
ever, there is also fat in other places such
as the liver and around the kidneys that
persists in both groups.
Inapreviousstudy,Tho ¨rneetal.(10)
compared the results of adjustable gastric
banding (AGB) versus AGB accompanied
by omentectomy in 37 morbidly obese
patients (18 with AGB and 19 with AGB
omentectomy)whocompleteda2-year
follow-up. Weight of the resected omen-
tum was similar to that of our patients.
The authors found a signiﬁcantly higher
weight reduction in the group of patients
with omentectomy (9  6 vs. 13  5 kg/
m
2, P  0.049) and signiﬁcantly lower
values of fasting glucose (0.7  0.7 vs.
1.8  0.8 mmol/l, P  0.04). A tendency
to a higher reduction of total cholesterol
values was also reported. A potential lim-
itation to interpret their results is that the
group of patients who underwent omen-
tectomyalsohadahigherweightlossdur-
ing the study period. Csendes et al. (23)
also performed a comparative evaluation
of patients with morbid obesity who un-
derwent LRYGB alone or combined with
omentectomy. Two years after surgery,
theyfoundnodifferencesbetweengroups
in terms of BMI, serum glucose, insulin,
totalcholesterol,triglycerides,andthebe-
havior of blood pressure.
In this study, where patients under-
going LRYGB and the combination of
LRYGB with omentectomy had similar
weight loss, we were unable to demon-
strate a signiﬁcant additional impact of
omentectomy on the components of met-
abolic syndrome, acute-phase reactants,
andinﬂammatorymediators.Ourcurrent
results and those from other published
seriesinhumanssuggestthattheaddition
of omentectomy to the LRYGB in patients
with G-III O and metabolic syndrome is
not justiﬁed.
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